CDK4/6 inhibition triggers anti-tumour immunity.

导出 OA

翻译打印收藏纠错

作者： Shom,Goel ^[1] ; Molly J,DeCristo ^[2] ; April C,Watt ^[3] ; Haley,BrinJones ^[4] ; Jaclyn,Sceneay ^[1] ; Ben B,Li ^[1] ; Naveed,Khan ^[3] ; Jessalyn M,Ubellacker ^[4] ; Shaozhen,Xie ^[1] ; Otto,Metzger-Filho ^[1] ; Jeremy,Hoog ^[3] ; Matthew J,Ellis ^[4] ; Cynthia X,Ma ^[1] ; Susanne,Ramm ^[2] ; Ian E,Krop ^[5] ; Eric P,Winer ^[6] ; Thomas M,Roberts ^[5] ; Hye-Jung,Kim ^[7] ; Sandra S,McAllister ^[8] ; Jean J,Zhao ^[2]

作者单位： Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA. ^[1] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA. ^[2] Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA. ^[3] Hematology Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA. ^[4] Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri 63110, USA. ^[5] Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas 77030, USA. ^[6] Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, Boston, Massachusetts 02115, USA. ^[7] Renal Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA. ^[8] Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA. ^[9] Department of Microbiology and Immunobiology, Division of Immunology, Harvard Medical School, Boston, Massachusetts 02115, USA. ^[10] Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts 02115, USA. ^[11] Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, USA. ^[12] Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, USA. ^[13]